Skip NavigationSkip to Content
Return Return to Search Results

Antineoplastic Agents 365 - Dolastatin 10 Sar Probes

  1. Author:
    Pettit, G. R.
    Srirangam, J. K.
    Barkoczy, J.
    Williams, M. D.
    Boyd, M. R.
    Hamel, E.
    Pettit, R. K.
    Hogan, F.
    Bai, R. L.
    Chapuis, J. C.
    McAllister, S. C.
    Schmidt, J. M.
    1. Year: 1998
  2. Journal: Anti-Cancer Drug Design
    1. 13
    2. 4
    3. Pages: 243-277
  4. Type of Article: Article
  1. Abstract:

    The remarkable anticancer drug dolastatin 10(1a) from the Indian Ocean sea hare Dolabella auricularia is currently undergoing phase I clinical trials Thirty-eight new structural modifications of this unusual peptide have been synthesized and evaluated against a variety of human and murine cancer cell lines, and for their ability to inhibit tubulin polymerization and vinblastine and GTP binding to tubulin. Dolastatin 10 and one structural modification was found to have antifungal activity, while one other structural modification of the parent compound exhibited antibacterial activity. Some of the new peptides approximated the antineoplastic potency of dolastatin 10, especially those based on replacement of the Doe unit with Met, Phe or an appropriately substituted phenylethylamide. [References: 32]

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel